The stakes of this work are considerable. According to the landmark global burden analysis cited by the authors, infections caused by 33 bacterial pathogens were associated with an estimated 7.7 million deaths in 2019, roughly one in eight deaths worldwide. Antimicrobial resistance directly accounted for 1.27 million of those deaths and contributed to nearly 5 million more. Five bacterial species in particular, Staphylococcus aureus, Escherichia coli, Streptococcus pneumoniae, Klebsiella pneumoniae, and Pseudomonas aeruginosa, were responsible for more than half of these fatalities, driven largely by infections of the lower respiratory tract, bloodstream, and abdominal cavity. With resistance continuing to spread, medicinal chemists are increasingly turning to scaffold modification and hybrid drug design to extend the useful life of existing antibiotic classes.

Ciprofloxacin, the starting point for the new study, is a second-generation fluoroquinolone that treats a broad range of infections affecting the respiratory tract, urinary tract, skin, and soft tissues. The drug works by inhibiting two essential bacterial enzymes, DNA gyrase and topoisomerase IV, which are required for DNA replication, transcription, and repair. This dual-target mechanism makes ciprofloxacin highly effective against many Gram-negative bacteria and active against several Gram-positive pathogens, including S. aureus and Enterococcus faecalis. However, resistance has steadily eroded its clinical utility, prompting ongoing efforts to design analogues with improved potency and resistance profiles.

The antibacterial efficacy of fluoroquinolones is strongly influenced by targeted modifications to the core quinolone scaffold, particularly at the C7 position. Substituting bulky heterocycles such as piperazinyl or pyridinyl groups at this position has been shown to enhance penetration into Gram-positive bacteria and increase binding affinity for DNA gyrase. The bicyclic 2,8-diazabicyclo[4.3.0]nonane moiety found in moxifloxacin, a fourth-generation fluoroquinolone, confers up to four-fold greater potency against Gram-positive pathogens relative to ciprofloxacin. Previous studies have also shown that spirocyclic groups at C7 can yield derivatives with improved activity, while research groups led by Foroumadi and Emami have explored aromatic nitrofluoroquinolones and ciprofloxacin-nitrofuran hybrids linked by methylene bridges, respectively, with encouraging results against Gram-positive organisms.

The rationale for incorporating a nitrofuran group draws on the distinctive biology of nitrofuran drugs such as nitrofurantoin. These compounds derive their broad-spectrum activity from nitroreductase-mediated free radical generation that damages bacterial DNA and proteins. Notably, nitrofurans maintain efficacy against multidrug-resistant Gram-positive pathogens, including methicillin-resistant S. aureus and vancomycin-resistant enterococci. Because their mechanism involves both DNA damage and protein inactivation, resistance is thought to develop less readily than against single-target antibiotics. The research team had previously reported ND-7901, a nitrofuran-benzimidazole with impressive potency against drug-resistant S. aureus, and hypothesized that fusing the nitrofuran functionality directly onto the ciprofloxacin core could combine the strengths of both pharmacophores.

The synthesis produced five compounds for evaluation. Compounds 8 and 9 were prepared by coupling ciprofloxacin with furan-2-carboxylic acid and 5-nitrofuran-2-carboxylic acid respectively, using standard EDC-mediated amide bond-forming conditions. A spirocyclic diamine analogue, compound 12, was synthesized through a nucleophilic aromatic substitution reaction between tert-butyl 3,9-diazaspiro[5.5]undecane-3-carboxylate and a difluoroquinoline intermediate, followed by deprotection. Compounds 10 and 11 extended this spirocyclic scaffold with furan and nitrofuran groups. The furan analogues lacking the nitro group served as critical controls, allowing the team to isolate the specific contribution of the reducible nitro functionality to antibacterial activity.

The results were striking. Compound 9, in which the nitrofuran is attached to the standard ciprofloxacin piperazine, showed an eight-fold increase in potency against the ciprofloxacin-resistant S. aureus strain ISR14-002 compared with ciprofloxacin itself, and more than a ten-fold improvement against S. aureus SG511. Compound 11, which combines both the nitrofuran and the novel spirocyclic diamine substitution, achieved a sixteen-fold potency increase against ISR14-002 relative to the parent spirocyclic amine and the furan derivative. Compound 9 also demonstrated significant activity against ciprofloxacin-resistant strains of Enterococcus faecalis, Burkholderia cenocepacia, and Burkholderia dolosa. In contrast, the simple furan analogue 8 conferred no potency gain, underscoring that the nitro group is essential to the observed enhancement.

Control experiments reinforced the conclusion that the hybrid molecules are genuinely synergistic rather than merely additive. When a one-to-one mixture of ciprofloxacin and 5-nitrofuran-2-carboxylic acid was tested against all strains, including S. aureus ISR14-002, the mixture performed no better than ciprofloxacin alone, and the free nitrofuran acid showed negligible activity by itself, with minimum inhibitory concentrations exceeding 25 micromolar against all strains tested. This demonstrates that the nitrofuran moiety must be covalently incorporated into the ciprofloxacin scaffold to achieve the dramatic potency gains, meaning the hybrid was far more potent than the sum of its parts.

The activity gains were not universal, however. Against Neisseria meningitidis and Neisseria gonorrhoeae, incorporation of either furan or nitrofuran moieties, as well as spirocyclic substitution, all diminished antibacterial potency compared with ciprofloxacin. The authors hypothesize that these species-specific differences may relate to differential reductive activation of the nitrofuran moiety, a mechanism suggested in prior literature but not yet experimentally validated in this study. The findings highlight the importance of pathogen-specific structure-activity relationships: nitrofuran substitution appears to selectively enhance activity against certain Gram-positive organisms, specifically S. aureus and E. faecalis, and against Gram-negative Burkholderia species, but its benefit does not extend to all targeted bacteria.

In vivo testing using the Galleria mellonella wax worm infection model provided an initial assessment of therapeutic potential. When larvae were infected with S. aureus SG511, nearly 95 percent of untreated worms died within three days, but administration of compound 12 at a dose of 5 micrograms per worm rescued over 65 percent of the larvae, comparable to the 60 percent rescue achieved with ciprofloxacin at the same dose. Against the ciprofloxacin-resistant ISR14-002 strain, which killed 85 percent of untreated worms by day two, neither ciprofloxacin nor any of the five test compounds produced a clear survival benefit at the single dose tested. Cytotoxicity screening in HepG2 liver cells, conducted under both glucose and galactose conditions to distinguish general from mitochondrial toxicity, showed that several compounds were comparable to or less toxic than ciprofloxacin. The authors note that differences between in vitro potency and in vivo efficacy may reflect pharmacokinetic properties, and they call for dose-ranging, pharmacokinetic, and further in vivo studies to determine whether the promising laboratory activity of these nitrofuran-ciprofloxacin hybrids can be translated into effective treatments for resistant infections.

Subject of Research: Design and evaluation of nitrofuran-containing ciprofloxacin analogues active against ciprofloxacin-resistant Staphylococcus aureus

Article Title: In vitro activity and comparative efficacy of novel nitrofuran-containing ciprofloxacin analogs against bacterial pathogens including ciprofloxacin-resistant Staphylococcus aureus

Article References: Marshall, K., Miller, P. A., Coates, R. M., Lawson-Rulli, J. M., Moraski, G. C., Miller, M. J., & Yano, M. (2026). In vitro activity and comparative efficacy of novel nitrofuran-containing ciprofloxacin analogs against bacterial pathogens including ciprofloxacin-resistant Staphylococcus aureus. The Journal of Antibiotics. https://doi.org/10.1038/s41429-026-00963-7

Image Credits: AI Generated

DOI: 10.1038/s41429-026-00963-7

Keywords: antimicrobial resistance, ciprofloxacin, nitrofuran, Staphylococcus aureus, fluoroquinolones, antibiotics, medicinal chemistry, drug design, Galleria mellonella, minimum inhibitory concentration, Burkholderia, structure-activity relationship